Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment: Clinical Trials Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment

 

Overview:

Acute Respiratory Distress Syndrome is an acute lung dysfunction, which occurs as a result of injury or illness. It is known as adult respiratory distress syndrome, it may also affect children. In this condition small air sacs (alveoli) in lungs are accumulated with fluid which makes difficulty in passing of oxygen into blood stream. Symptoms of acute respiratory distress syndrome includes difficulty in breathing, rapid breathing, hyper ventilation. ARDS can be developed into deep infection which causes pneumonia, trauma.

ARDS can be diagnosed by blood tests, chest x-rays and others. Treatment for the ARDS are mechanical ventilation, supplemental oxygen, fluid management and a technique called positive end expiratory pressure (PEEP) to help push the fluid out of air sacs, extracorporeal membrane oxygenation, human mesenchymal stem cells.

 

Segmentation:

By Drugs, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:

• Interferon Beta-1a
• Imatinib
• Sivelestat
• L-Citrulline
• Poractantalfa
• Ganciclovir
• Others

By Route of Administration, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:

• Oral
• Parenteral

By Trial Phase, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:

• Preclinical Trials
• Phase 1
• Phase 2
• Phase 3
• Phase 4

By Company, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:

• AltorBioScience
• Genentech, Inc.
• Faron Pharmaceuticals Ltd.
• AltorBioScience
• Suntory Pharmaceutical
• Eli Lilly and Company
• Asklepion Pharmaceuticals, LLC
• BioMarck Pharmaceuticals, Ltd.
• Others

 

Space Analysis:

• In January 2016, Chiesi Farmaceutici S.p.A initiated phase II clinical trials of its CHF 5633 in neonatal respiratory distress syndrome.
• In August 2017, BioMarck Pharmaceuticals initiated Phase-II clinical trials in Adult respiratory distress syndrome in USA (Inhalation)

 

Report Description:

Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Acute Respiratory Distress Syndrome treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Acute Respiratory Distress Syndrome disease pipeline drugs development. This report studies the dynamics of the Acute Respiratory Distress Syndrome Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Acute Respiratory Distress Syndrome disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis on the each drug candidates in the clinical trial phases

 

• AltorBioScience
• Genentech, Inc.
• Faron Pharmaceuticals Ltd.
• AltorBioScience
• Suntory Pharmaceutical
• Eli Lilly and Company
• Asklepion Pharmaceuticals, LLC
• BioMarck Pharmaceuticals, Ltd.

1. Executive Summary

 

2. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Introduction

 

2.1. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Taxonomy

2.2. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market –Definitions

2.2.1. Drugs

2.2.2. Route of Administration

2.2.3. Trial Phase

 

3. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics

 

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamic Factors – Impact Analysis

3.6. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Competition Landscape

3.7. Epidemiology

 

4. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024

 

4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market opportunity analysis

 

5. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market, By Drugs, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

5.1. Interferon Beta-1a

5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

 

5.2. Imatinib

5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

 

5.3. Sivelestat

5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

 

5.4. L-Citrulline

5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.4.3. Market Opportunity Analysis

 

5.5. Poractantalfa

5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.5.3. Market Opportunity Analysis

 

5.6. Ganciclovir

5.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.6.3. Market Opportunity Analysis

 

5.7. Others

5.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.7.3. Market Opportunity Analysis

 

6. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Forecast, By Route of Administration,2013 – 2017 and Forecast, 2017 – 2024

 

6.1.  Oral

6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

 

6.2. Parenteral

6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

 

7. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Forecast, By Trial Phase, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

7.1. Preclinical Trials

7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Phase 1

7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

 

7.3. Phase 2

7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

 

7.4. Phase 3

7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.4.3. Market Opportunity Analysis

 

7.5. Phase 4

7.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.5.3. Market Opportunity Analysis

 

8. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

8.1. North America

8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

 

8.2. Europe

8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

 

8.3. Asia-Pacific

8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

 

8.4. Latin America

8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.4.3. Market Opportunity Analysis

 

8.5. Middle East and Africa

8.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.5.3. Market Opportunity Analysis

 

8.6. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024

 

9. North America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

9.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

9.1.1. Interferon Beta-1a

9.1.2. Imatinib

9.1.3. Sivelestat

9.1.4. L-Citrulline

9.1.5. Poractantalfa

9.1.6. Ganciclovir

9.1.7. Others

 

9.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.2.1. Oral

9.2.2. Parenteral

 

9.3. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.3.1. Preclinical Trials

9.3.2. Phase 1

9.3.3. Phase 2

9.3.4. Phase 3

9.3.5. Phase 4

 

9.4. Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.4.1. U.S.

9.4.2. Canada

 

9.5. North America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024

9.6. North America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends

 

10. Europe Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

10.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

10.1.1. Interferon Beta-1a

10.1.2. Imatinib

10.1.3. Sivelestat

10.1.4. L-Citrulline

10.1.5. Poractantalfa

10.1.6. Ganciclovir

10.1.7. Others

 

10.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Oral

10.2.2. Parenteral

 

10.3. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.3.1. Preclinical Trials

10.3.2. Phase 1

10.3.3. Phase 2

10.3.4. Phase 3

10.3.5. Phase 4

 

10.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.4.1. Germany

10.4.2. UK

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Russia

10.4.7. Poland

10.4.8. Rest of Europe

 

10.5. Europe Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024

10.6. Europe Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends

 

11. Asia-Pacific Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

11.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

11.1.1. Interferon Beta-1a

11.1.2. Imatinib

11.1.3. Sivelestat

11.1.4. L-Citrulline

11.1.5. Poractantalfa

11.1.6. Ganciclovir

11.1.7. Others

 

11.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Oral

11.2.2. Parenteral

 

11.3. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.3.1. Preclinical Trials

11.3.2. Phase 1

11.3.3. Phase 2

11.3.4. Phase 3

11.3.5. Phase 4

 

11.4. Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)       

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. ASEAN

11.4.5. Australia & New Zealand

11.4.6. Rest of Asia-Pacific

 

11.5. Asia-Pacific Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024

11.6. Asia-PacificAcute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends

 

12. Latin America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2012 – 2012 – 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

12.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

12.1.1. Interferon Beta-1a

12.1.2. Imatinib

12.1.3. Sivelestat

12.1.4. L-Citrulline

12.1.5. Poractantalfa

12.1.6. Ganciclovir

12.1.7. Others

 

12.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Oral

12.2.2. Parenteral

 

12.3. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.3.1. Preclinical Trials

12.3.2. Phase 1

12.3.3. Phase 2

12.3.4. Phase 3

12.3.5. Phase 4

 

12.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Argentina

12.4.4. Venezuela

12.4.5. Rest of Latin America

 

12.5. Latin America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024

12.6. Latin America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends

 

13. Middle East and Africa Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

13.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

13.1.1. Interferon Beta-1a

13.1.2. Imatinib

13.1.3. Sivelestat

13.1.4. L-Citrulline

13.1.5. Poractantalfa

13.1.6. Ganciclovir

13.1.7. Others

 

13.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.2.1. Oral

13.2.2. Parenteral

 

13.3. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.3.1. Preclinical Trials

13.3.2. Phase 1

13.3.3. Phase 2

13.3.4. Phase 3

13.3.5. Phase 4

 

13.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

13.4.1. Gulf Cooperation Council (GCC) Countries

13.4.2. Israel

13.4.3. South Africa

13.4.4. Rest of MEA

 

13.5. MEA Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024

13.6. MEA Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends

 

14. Competition Landscape

 

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. AltorBioScience

14.2.2. Genentech, Inc.

14.2.3. Faron Pharmaceuticals Ltd.

14.2.4. AltorBioScience

14.2.5. Suntory Pharmaceutical

14.2.6. Eli Lilly and Company

14.2.7. Asklepion Pharmaceuticals, LLC

14.2.8. BioMarck Pharmaceuticals, Ltd.

14.2.9. Others

 

15. Research Methodology

16. Key Assumptions and Acronyms

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

ASK AN ANALYST